Abrégé

The present disclosure relates to methods of screening salmonids for increased resistance to viral infection, such as infectious pancreatic necrosis virus (IPNV) infection. The present disclosure also relates to fish which have been genetic modified to have increased resistance to viral/IPNV infection. The present disclosure further relates to the use of these fish, which have been identified, or genetically modified to have increased genetic resistance, in aquaculture breeding programs and/or production. The present disclosure further relates to the use of small molecules which target NAE1 and their use in therapy or prevention of viral/IPNV infection.

Classes IPC  ?

• C07K 14/46 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present disclosure relates to the development of novel cleavable peptide probes for use in detecting granzyme B, as well as methods for using the probes in medical and biological settings. The probes may comprise a fluorescent moiety conjugated or bound to the peptide, and quencher moiety conjugated or bound to the peptide and upon cleavage of the peptide, the fluorescent moiety becomes dequenched.

Classes IPC  ?

• C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides

Abrégé

The disclosure relates to synthetic super-enhancers activated by one or more transcription factors. In particular, the present disclosure describes synthetic super-enhancers that are activated by one or more transcription factors expressed in a target cell and used to express transgenes, such as adverse payloads, upon activation of the synthetic super-enhancer by the transcription factor(s).

Classes IPC  ?

• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/861 - Vecteurs adénoviraux

Abrégé

A system to limit the expression of a vector-derived transgene within a window that alleviates the disease-causing genetic deficiency without producing overexpression toxicity is described. This provides for 'dosage-insensitivity', whereby cells or tissues receiving more vector-derived transgene are disproportionately suppressed through an in-built single gene circuit that can regulate adaptively.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées

Abrégé

The improved 4-5 day, optionally 3-5 day GMP-compliant in-vitro method enables the production of macrophages from monocytes that benefits from a shorter cell culture time, fewer interventions whilst maintaining the desired characteristics of the human macrophages. The present invention describes a method wherein the monocytes are cultured in medium comprising one or more growth factors to stimulate macrophages with a pro-regenerative phenotype. The method described herein is xeno-free, serum-free and GMP compliant. In addition, further disclosed are macrophages produced according to the present invention and the use of said macrophages in the treatment of liver diseases, such as liver cirrhosis.

Classes IPC  ?

• C12N 5/0786 - Monocytes; Macrophages

Abrégé

Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response and/or express a transgene in a subject in need thereof.

Classes IPC  ?

• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• A61K 39/235 - Adenoviridae
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61P 37/04 - Immunostimulants
• C07K 14/075 - Adénoviridae
• C07K 19/00 - Peptides hybrides
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
• C12N 15/34 - Protéines de virus à ADN
• C12N 15/861 - Vecteurs adénoviraux

Abrégé

There is discussed nematode antigens capable of causing an immune response in a host such that a protective effect is provided to the host in relation to the nematode. Antigens, compositions for the treatment of parasitic nematode infections, methods of prophylaxis and treatment of parasitic nematode infections, and vaccines to reduce and / or control parasitic nematode infections are provided.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 33/10 - Anthelmintiques
• C07K 14/435 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains

Abrégé

Aspects of the present disclosure relate to genetically altered plants having a modified Rubisco and further having a modified Essential Pyrenoid Component 1 (EPYC1) for formation of an aggregate of modified Rubisco and EPYC1 polypeptides. Other aspects of the present disclosure relate to methods of making such plants as well as cultivating these genetically altered plants.

Classes IPC  ?

• C07K 14/415 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de végétaux
• C12N 9/88 - Lyases (4.)
• C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales

Abrégé

There is provided an in vitro three dimensional cell construct for use as a model of the avian intestine derived from avian intestinal tissue comprising avian cells organised into intestinal villi and crypts. Suitably the construct comprises an exterior surface that mimics the apical surface of a chicken intestine. Also provided are methods of making the cell construct and use of the construct as an in vitro intestinal model system to examine an agent including, but not limited to a microbe, a vaccine, a pharmaceutical, a feed additive, a toxin, a pre-biotic, post-biotic, pre pro post biotic, therapeutic, a cell, gene construct, protein, immune-modulator, an intestinal effector agent, a candidate intestinal effector agent, cell signalling inhibitor, or cell signalling activator.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet

Abrégé

Disclosed herein transgene construct comprising (i) a first nucleotide sequence, wherein the activity of the protein encoded by said first nucleotide sequence causes death of germ cells in the presence of an exogenous induction agent and (ii) a second nucleotide sequence which targets said construct to avian germ cells, methods of using the same and a transgenic avian provided by such methods.

Classes IPC  ?

• A01K 67/027 - Nouvelles races de vertébrés
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

The present invention relate to autologous isolated unpolarized human macrophages for use in the treatment of liver disease and macrophages for use in a method of treating fibrosis in a human in need thereof.

Classes IPC  ?

• A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

MECP2 EXPRESSION CASSETTES. The present invention provides nucleic acid molecules comprising a MeCP2 expression cassette, the expression cassette comprising, in operable linkage from 5' to 3': a 5' transcriptional control region comprising a promoter capable of driving transcription in neural cells; an open reading frame encoding a MeCP2 protein; translation control signals; a 3' untranslated region (3'UTR) comprising one or more of: (i) a binding site for mir-22; (ii) a binding site for mir-19; (iii) a binding site for miR-132; (iv) a binding site for miR124; and (v) an AU-rich element; and transcriptional termination signals; wherein the MeCP2 expression cassette is not more than about 5 kb in length. The invention further provides viral vectors, especially vectors derived from adeno-associated virus (AAV), for use in therapeutic delivery of such expression cassettes. The nucleic acid molecules and viral vectors disclosed herein provide novel tools for expressing MeCP2 and are of particular value in the treatment of disorders associated with reduced MeCP2 activity, including Rett syndrome.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Abrégé

MeCP2 based therapy. The present invention relates to synthetic polypeptides that are useful in the treatment of disorders associated with reduced MeCP2 activity, including Rett syndrome. The present invention provides synthetic polypeptides comprising: i) an MBD amino acid sequence showing at least 70% similarity with the amino acid sequence as depicted in SEQ ID NO: 1; and ii) an NID amino acid sequence showing at least 70% similarity with the amino acid sequence as depicted in SEQ ID NO: 2, wherein the polypeptide has a deletion of at least 50 amino acids, when compared to the full length MeCP2 e1 and e2 sequences. The invention further provides nucleic acid constructs, expression vectors, virions, pharmaceutical compositions, and cells providing polynucleotides of the invention. The invention further provides methods of treating or preventing disease in an animal comprising administering to said animal a synthetic polypeptide according to the invention.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Abrégé

A method of detecting the presence of alpha-synuclein aggregation in a biological sample is provided whereby a biological sample is mixed with a reaction sample comprising a population of beads, a fluorophore adapted to bind to protein aggregates and to increase fluorescence when bound to protein aggregates, and alpha-synuclein or a fragment or variant thereof to form a reaction mixture, the reaction mixture is illuminated and at the same time incubated with intermittent agitation cycles, wherein a significant increase in the fluorescence of the reaction mixture during incubation is indicative of the presence of aggregates of alpha-synuclein in the biological sample. Method of diagnosing alpha-synucleinopathies such as Parkinson's disease or Dementia with Lewy Bodies.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/538 - 1,4-Oxazines, p.ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
• A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p.ex. enzymes pancréatiques
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

A first aspect of the- invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, (Formula (I)) wherein: R1 is (CH2)mNR11R12;R2 is selected from H, halo, OR13, ??R13, alkyl, alkenyl and alkynyl; R3 is selected from alkyl, alkenyl, alkynyl, aryl, halo, aryloxy, NHCO2R4, NHCONR5R6, NHCOR7, NH-alkyl, NH-alkenyl, NH(CH2);n-aryl, (CH2)p-heteroaryl, (CH2)qCO2R8, (CH2)rCOR9 and NHSO2R10, wherein each alkyl, alkenyl, aryl or heteroaryl moiety in the aforementioned list is optionally further substituted by one or more groups selected from alkyl, halo OH, NH2, alkoxy, aryloxy, alkylamino, arylamino, carboxyl and carboxamide; R4 to R10 and R13 are each independently selected from alkyl, alkenyl and aryl; R11 and R12 are each independently selected from alkyl and alkenyl; or R11 and R:12 are linked together with the nitrogen to which they are attached to form a heterocycloalkyl or heterocycloalkenyl group; n, m, p, q and r are each independently selected from 0, 1, 2,.3. 4, 5 and 6. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing according to the invention.

Classes IPC  ?

• C07D 487/04 - Systèmes condensés en ortho
• A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 31/12 - Antiviraux
• A61P 35/00 - Agents anticancéreux

Abrégé

Compound of formula (I) wherein R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or =O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disewase, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/423 - Oxazoles condensés avec des carbocycles
• A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
• A61K 31/501 - Pyridazines; Pyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 31/00 - Agents anti-infectieux, c. à d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

The present invention provides livestock animals and methods to create recipient animals for spermatogonial stem cell transplantation through modulation of the NANOS gene. In one embodiment genome editing issued to create animals with insertions or deletions (indels) that inactivate or otherwise modulate NANOS gene activity so that resulting males lack functional germ cells yet retain functional somatic cells, and females are fertile. These males can then be transplanted with donor spermatogonial stem cells and used for breeding.

Classes IPC  ?

• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
• C12N 5/076 - Cellules du sperme; Spermatogonies
• A01K 67/027 - Nouvelles races de vertébrés
• C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
• C12N 15/09 - Technologie d'ADN recombinant
• C12N 15/12 - Gènes codant pour des protéines animales
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

A compound of formula (I) or a salt thereof are provided wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Classes IPC  ?

• C07D 263/58 - Benzoxazoles; Benzoxazoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement en position 2
• A61K 31/423 - Oxazoles condensés avec des carbocycles
• A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
• A61K 31/501 - Pyridazines; Pyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons

Abrégé

A communications system having at least one transmitter for transmitting one or more signals and at least one receiver for receiving the one or more signals, wherein the transmitters and/or receivers have an angular dependence, such that at least one response of the receivers to a received signal and/or at least one property of the signals transmitted by the transmitters is angularly dependent; the receiver and transmitter and/or the signals transmitted by the transmitters of two or more transmitter-receiver pairs have a distinct associated angular arrangement or relationship, wherein the at least one angularly dependent response of the receivers to the signal and/or the at least one angularly dependent property of the signal is dependent on the angular arrangement or relationship; and the system is configured to use the angularly dependant property and/or response to identify or discriminate the transmitter from which the signal was transmitted and/or at least one communication channel associated therewith. Associated receivers, transmitters, devices and methods are also provided.

Classes IPC  ?

• H04B 10/112 - Transmission dans la ligne de visée sur une distance étendue
• H04B 10/116 - Communications par lumière visible
• H01S 5/00 - Lasers à semi-conducteurs
• H04J 11/00 - Systèmes multiplex orthogonaux
• H04B 7/024 - Utilisation coopérative d’antennes sur plusieurs sites, p.ex. dans les systèmes à plusieurs points coordonnés ou dans les systèmes coopératifs à "plusieurs entrées plusieurs sorties" [MIMO]

Abrégé

A receiver system (100) having at least one receiver(101)for receiving optical communications signals(103b)that encode or transmit information; wherein the receiver system (100) is adapted to produce one or more electrical signals(104)from the received optical signal(103b)and/or from ambient light(103a)such that the receiver system (100) is usable as a source of electrical power and the encoded or transmitted information from the received optical communication signal(103b)is recovered or recoverable from the electrical signal(s)(104). Embodiments of the invention also relate to a communications system(400)that further comprises one or more transmitters(406)and a device having the receiver systems(401), along with associated methods of using and producing. Particular embodiments relate to identification tags(1000)and user devices(300)having a display(301)that at least partially overlaps the receiver(s)(302).

Classes IPC  ?

• H04B 10/116 - Communications par lumière visible
• H04B 10/80 - Aspects optiques concernant l’utilisation de la transmission optique pour des applications spécifiques non prévues dans les groupes , p.ex. alimentation par faisceau optique ou transmission optique dans l’eau
• G06K 19/07 - Supports d'enregistrement avec des marques conductrices, des circuits imprimés ou des éléments de circuit à semi-conducteurs, p.ex. cartes d'identité ou cartes de crédit avec des puces à circuit intégré

Abrégé

The present invention provides a recombinant protein capable of binding to complement factor H (CFH), and thereby inducing increased binding of C3d and C3b by bound CFH compared to unbound CFH. Methods and medical devices for using utilising the same are also described.

Classes IPC  ?

• C07K 14/315 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Streptococcus (G), p.ex. Enterocoques

Abrégé

The present invention relates to methods of visualising cells especially although not exclusively in vivo using a dye, such as a dendrimer-dye molecule or polybranched- dye molecule which is internalised by the cells and thus permits subsequent visualisation by confocal fluorescence endomicroscopy or other optical detectors. There is also provided internally quenched probes for use in visualising cells especially although not exclusively in vivo by confocal fluorescence endomicroscopy and the use of internally quenched probes in combination with confocal fluorescence endomicroscopy, for visualising cells by virtue of internalisation and dequenching of a probe by the cells. In a particular embodiment the cells are activated neutrophils, such as within the lung of a subject.

Classes IPC  ?

• A61K 49/00 - Préparations pour examen in vivo

Abrégé

Compositions and methods for use of TALENs to make genetically modified livestock are set forth. The methods may include reporters for selecting cells or embryos that have been modified by TALENs for use as progenitor cells to make founder animals.

Classes IPC  ?

• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus

Abrégé

The present invention provides modified nucleobase compounds, modified nucleic acid mimetic compounds and various uses thereof. In addition, the invention provides methods for nucleobase characterisation, SNP characterisation and nucleic acid sequencing.

Classes IPC  ?

• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 471/04 - Systèmes condensés en ortho
• C07D 473/18 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 un atome d'oxygène et un atome d'azote, p.ex. guanine
• C07D 473/34 - Atome d'azote lié en position 6, p.ex. adénine
• C07D 493/10 - Systèmes condensés en spiro
• C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
• C07H 21/00 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques

Abrégé

A system for testing visual fields comprising a display for presenting a visual stimulus and an eye tracker for tracking movement of at least one of a patient's eyes to determine its position in three dimensions without requiring the patient to wear any tracking equipment. A computer controls the position of the stimulus on the display and causes it to move by an amount that is a function of the tracked three-dimensional position of the patient's eye and a visual field position that is to be tested. Changes to the position of the stimulus and any corresponding tracked eye movement are used to assess the patient's visual field.

Classes IPC  ?

• A61B 3/024 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure subjective, c. à d. appareils de d’examen nécessitant la participation active du patient pour la détermination du champ de vision, p.ex. périmètres

Abrégé

The present invention relates to a bifunctional material which comprises copper and which is capable of storing nitric oxide (NO), as well as catalytically producing nitric oxide from a suitable precursor. The material typically comprises a zeolite and the copper may be part of, or separate from the zeolite. In this manner, the material may comprise a single bifunctional material; that is, a material which is capable of both storing NO and catalytically producing NO, such as Cu-MFT or Cu-X. Alternatively the material may comprise at least two components, a first component to store NO, such as a zeolite Zn-LTA, and a further component comprising Cu(I), such as Cu2O, to catalytically produce NO from a suitable precursor. The bifunctional material is used in a pharmaceutical, neutraceutical or cosmetic preparation, or comprised in a medical article, a cosmetic and/or personal hygiene product.

Classes IPC  ?

• B01J 20/18 - Tamis moléculaires zéolitiques synthétiques
• A61K 8/19 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés inorganiques
• A61K 33/34 - Cuivre; Ses composés
• A61L 29/16 - Matériaux biologiquement actifs, p.ex. substances thérapeutiques
• A61L 31/16 - Matériaux biologiquement actifs, p.ex. substances thérapeutiques
• B01J 29/072 - Métaux du groupe du fer ou cuivre

Abrégé

The invention relates to a generator, to a magnetic flux conducting unit for a generator, and to a power generation machine comprising such a generator. In an embodiment of the invention, a generator (412) is disclosed which comprises at least one coil assembly (428) and at least one magnetic flux conducting unit (410). The magnetic flux conducting unit (410) comprises at least one magnet (314, 316), a pair of opposed magnetic flux conducting elements (318, 320) defining a space (326) therebetween for receiving the coil assembly (428), and at least one connecting portion (322) extending between the opposed magnetic flux conducting elements (318, 320). The at least one magnet (314, 316) is arranged relative to the opposed magnetic flux conducting elements (318, 320) such that magnetic attraction forces between the elements (318, 320) are reacted through and balanced within the connecting portion (322).

Classes IPC  ?

• H02K 23/54 - Moteurs ou génératrices à induit en forme de disque

Abrégé

The invention relates to a method and apparatus for remediating land (10) that is contaminated by a combustible material (12), in particular, land contaminated with non- aqueous phase liquids (NAPLs). In an embodiment of the invention, a method for remediating land that is contaminated by a combustible material is disclosed which includes the steps of locating a subterranean volume (16) of combustible material such as a DNAPL (12) in land (10) to be remediated, and igniting the combustible material (12) to combust the material and thereby remediate the land (10). By monitoring combustion of the material, combustion may be optimised by, for example, supplying an oxidant or a combustion suppressant.

Classes IPC  ?

• B09C 1/06 - Régénération de sols pollués par des procédés thermiques
• F23G 7/14 - Procédés ou appareils, p.ex. incinérateurs, spécialement adaptés à la combustion de déchets particuliers ou de combustibles pauvres, p.ex. des produits chimiques de sols pollués, p.ex. sols pollués par des huiles

Abrégé

A homogenous, symmetrically dividing population of adherent neural stem cells is obtained from ES cells or foetal or adult brain isolates, using an activator of a signalling pathway downstream of a receptor of the EGF receptor family, optionally in combination with an activator of a signalling pathway downstream of an FGF receptor. The neural stem cell population is highly pure and retains the ability to differentiate into neurons after in excess of 100 passages.

Classes IPC  ?

• C12N 5/0797 - Cellules souches; Cellules progénitrices
• C12N 5/0793 - Neurones
• C12N 15/873 - Techniques de production de nouveaux embryons, p.ex. transfert nucléaire, manipulation de cellules totipotentes ou production d'embryons chimériques
• A61K 35/30 - Nerfs; Cerveau; Yeux; Cellules cornéennes; Liquide céphalorachidien; Cellules souches neuronales; Cellules précurseurs neuronales; Cellules gliales; Oligodendrocytes; Cellules de Schwann; Astroglies; Astrocytes; Plexus choroïde; Tissu de moelle épinière
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
• C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p.ex. co-transformation